Who has been buying Next Biomedical stock?

3 distinct insiders have filed 2 disclosed insider purchases in Next Biomedical (389650), most recently on 2026-06-24. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Next Biomedical have?

Next Biomedical has 2 buy-side and 3 sell-side disclosures on record, covering ₩1.9B ($1.3M) in total reported value, spanning 2024-08-20 to 2026-06-24.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Next Biomedical 389650

Company

넥스트바이오메디컬Next Biomedical

Insiders

Buys

Total Value

₩1.9B ($1.3M)

Avg Return

-6.40%

Last Filing

2026-06-24

Next Biomedical (389650) has 2 disclosed insider purchases and 3 disclosed disposals on record, filed by 3 distinct insiders. Together those filings cover ₩1.9B ($1.3M) in reported transaction value. The earliest filing StockDrifts holds for Next Biomedical is dated 2024-08-20; the most recent is 2026-06-24. Across these filings the average return since disclosure is -6.40%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-06-24	BUY	Market Buy	남동흔 Nam Dong-heun	moving	1.0K	₩41,900	-9.9%	₩42M ($29K)
2026-06-18	BUY	Market Buy	강철중 Steel middle school	Managing Director	2.0K	₩40,150	-6.0%	₩80M ($56K)
2026-05-20	BUY	주식매수청구권 행사	한명식 Han Myeong-sik	moving	750	₩47,000	-6.6%	₩35M ($24K)
2026-05-01	BUY	신규선임	한명식 Han Myeong-sik	moving	1.0K	-	-	-
2025-12-01	SELL	Market Sell	이은혜 Eunhye Lee	Managing Director	-1.1K	₩89,000	+13.2%	₩96M ($66K)
2025-10-28	BUY	주식매수선택권	이은혜 Eunhye Lee	Managing Director	15.0K	₩63,400	+21.9%	₩951M ($660K)
2025-10-24	SELL	Market Sell	이은혜 Eunhye Lee	Managing Director	-9.4K	₩60,400	-28.0%	₩568M ($394K)
2025-09-08	SELL	Market Sell	이은혜 Eunhye Lee	Managing Director	-15.0K	₩76,300	-1.3%	₩1.1B ($795K)
2025-09-04	SELL	증여	이은혜 Eunhye Lee	Managing Director	-8.1K	₩69,900	-10.6%	₩564M ($392K)
2024-09-26	BUY	주식매수선택권	이은혜 Eunhye Lee	Managing Director	35.4K	₩43,750	+76.7%	₩1.5B ($1.1M)
2024-09-26	BUY	주식매수선택권	박세환 Park Se-hwan	Managing Director	21.6K	₩43,750	+76.7%	₩945M ($657K)
2024-09-26	BUY	주식매수선택권	홍순석 Soonseok Hong	moving	21.6K	₩43,750	+76.7%	₩945M ($657K)
2024-08-20	BUY	신규상장	이돈행 To this money	moving	2.1M	₩23,700	+226.2%	₩50.7B ($35.2M)
2024-08-20	BUY	신규상장	홍순석 Soonseok Hong	moving	15.0K	₩23,700	+226.2%	₩355M ($246K)
2024-08-20	BUY	신규상장	이득춘 Deukchun Lee	moving	31.5K	₩23,700	+226.2%	₩746M ($518K)
2024-08-20	BUY	신규상장	박세환 Park Se-hwan	moving	15.1K	₩23,700	+226.2%	₩357M ($248K)
2024-08-20	BUY	신규상장	이은혜 Eunhye Lee	moving	8.1K	₩23,700	+226.2%	₩191M ($133K)

Frequently asked questions

Who has been buying Next Biomedical stock?: 3 distinct insiders have filed 2 disclosed insider purchases in Next Biomedical (389650), most recently on 2026-06-24. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Next Biomedical have?: Next Biomedical has 2 buy-side and 3 sell-side disclosures on record, covering ₩1.9B ($1.3M) in total reported value, spanning 2024-08-20 to 2026-06-24.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.